You cannot register for this webinar

As part of the newly launched IACH Multiple Myeloma Academy, this high-stakes roundtable debate will challenge conventional thinking on autologous hematopoietic cell transplantation (HCT) in patients aged 65 to 70. With evolving therapies and shifting survival paradigms, should HCT remain the gold standard, or are we clinging to outdated dogma? Leading experts will go head-to-head on patient selection, survival vs. quality of life, and the rise of alternative treatments. Expect bold arguments, controversial takes, and audience engagement in this must-attend debate! Speakers: Meral Beksac Meletios Athanasios Dimopoulos Maria Victoria Mateos Manteca Cesar Rodriguez Facon Thierry Mohamad Mohty